Mazyar Shadman, MD, MPH
Every day, I get to integrate science with the art of human interaction. Seeing patients benefit from medical advances, and being active in pushing the science forward, is extremely rewarding. It’s an exciting time for both cancer care and research. We now have access to a variety of novel therapies that enable us to target cancer cells more specifically without causing major side effects. In my field, we’re always looking for a “cure,” but in the meantime, I’m hopeful that we can relegate cancer to a chronic disease and help patients maintain their desired quality of life.
A diagnosis of cancer kicks off a torrent of life changes, and in the middle of all this disruption are many important decisions to make about your care. My role is to help you thoroughly understand and weigh your options. At SCCA, you have access to a variety of standard and experimental treatments, from chemotherapy to more novel, targeted approaches that may have fewer side effects. We’ll discuss each option in detail — the potential benefits, the risks and the overall impact on your life and family — so that you can make the best choices for your unique situation.
Specialty: Medical Oncology
Adult Blood and Marrow Transplantation, Cellular Immunotherapy, Hematologic Malignancies
I am a medical oncologist and stem-cell transplant expert who specializes in treating patients with lymphomas and other blood disorders. My clinical trial work focuses on testing novel agents for the treatment of leukemia and lymphoma, with a particular focus on chronic lymphocytic leukemia (CLL). I also study the clinical outcomes of patients who have already been treated. My goal is to identify patient- or disease-specific characteristics that can help us understand the behavior of a disease and predict its responsiveness to different treatments. One particular area of interest is the epidemiology of hematologic neoplasms (abnormal growth in blood-forming tissue). In 2013, I co-authored a study that found a correlation between certain types of allergies and blood cancers.
Learn about the latest innovations in hematologic oncology.
Current treatment options of chronic lymphocytic leukemia (CLL) go far beyond chemotherapy. Thanks to novel agents like ibrutinib, acalabrutinib and venetoclax, there are now chemotherapy-free treatment options that can potentially minimize treatment time and side effects for every patient with CLL.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
SCCA’s Dr. Mazyar Shadman spoke with Healio about phase 1 study results presented at ASH.
Key research spans CAR T-cell therapies and treatments for myeloma, leukemia and more.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.